D. Wilson
Analyst · Credit Suisse
Thank you, Pierre, and good morning, everyone. I'm pleased to be with you today report on the current performance and outlook for our Specialty Chemicals group. After updating you on our second quarter performance, I'll provide insights into the growth strategies we're employing in BioPolymer and Lithium to deliver on our contribution to Vision 2015. First, a review of second quarter performance. Revenue in Specialty Chemicals was $229 million, up 6% versus the year ago quarter. Despite capacity constraints in Lithium, driven by higher selling prices in all businesses and strong volume growth in pharmaceutical ingredients and lithium specialties. BioPolymer achieved record sales and earnings in the quarter. The pharmaceutical ingredients sales gains were realized in all product segments, while food ingredient sales were driven by dairy and beverage markets in Asia, particularly China. Lithium sales growth was led by butyllithium, serving pharmaceutical and chemical synthesis markets. Given our lithium capacity constraints, we have delivered top line growth this year by increasing sales of higher value downstream products like butyllithium at the expense of upstream primary compounds sold into lower value segments. Of course, we've been careful to protect market share in key primary growth segments such as energy storage. Segment earnings of $56 million were 10% higher than the prior year quarter as a result of the strong commercial performance despite higher raw material cost and higher weather-related operating cost in Argentina. The wettest weather conditions in a decade in Argentina presented operational challenges in the quarter. Heavy rain and snow, which washed out and blocked roads, created logistical challenges impacting production yields and costs. While we believe the worst of the winter weather is now behind us, we expect to experience further production inefficiencies in the third quarter due to lower second quarter brine production and dilution of the lithium brines in the solar evaporation ponds by the heavy precipitation. This will effectively result in some shift in Lithium earnings from the third quarter to the fourth quarter. Moving to our outlook for the third quarter and the full year. We expect continued strong earnings performance across the segment. For the third quarter, we project earnings to increase approximately 5% as higher volumes and selling prices in BioPolymer and Lithium Specialties are partially offset by increased spending on growth initiatives, higher raw material cost and the weather-related lithium production issues in Argentina. For the full year, we project sales to be up mid-single digits, driven by continued volume growth and higher selling prices in BioPolymer and Lithium Specialties. Full year segment earnings are expected to be up approximately 10%, consistent with prior guidance. BioPolymers projected to achieve its seventh straight year of record earnings due to continued strong commercial performance, which will more than offset the impact of higher raw material costs. Lithium performance will benefit from the sales gains in Lithium Specialties. As a result, the Specialty Chemicals segment will deliver its sixth consecutive year of record earnings. Let me now turn to a more detailed review of the growth strategies we're employing in BioPolymer and Lithium to deliver on our Vision 2015 commitments. Achieving faster top line growth is an important element in realizing our 2015 objectives with Specialty Chemicals. Across the next 5 years, we see top line growth rising from its historical 6% to 7% level to approximately 10%. Driving this rate increase will be increasing sales of faster-growing product lines such as MCC for food ingredients and pharmaceuticals and lithium compounds for energy storage applications. Earnings will be enhanced by this mix shift. Though Specialty Chemicals has always had attractive operating margins, we plan to achieve operating margins of approximately 26% by 2015. Let's take a look at each business and how it will contribute to this even higher level of performance. Starting with Lithium. The business today accounts for approximately 30% of segment sales or approximately $220 million. We're the second largest supplier in terms of revenues with a broad market presence in both upstream primaries and downstream specialty. Our longer term outlook for lithium is as bullish as it's ever been. We expect to see continued strong demand in energy storage and synthesis applications drive global market growth. Overall, we forecast global lithium demand will grow at approximately 6% to 7% through the next 3 to 4 years. Going forward, the energy storage segment is expected to be the premium growth driver for the overall market. Traditional, non-transportation energy storage applications have been growing in the 15% range over the last 5 years. With the increasing focus on electric vehicles, the future growth of lithium to support new battery solutions is expected to be significant. We believe that lithium supplied to the transportation segment could account for over 40% of overall demand by 2020. Today, we also to our view [ph] -- 8 months ago at Investor Day, we see even more opportunities in transportation particularly in Asia for applications such as intercity buses and mopeds. Transportation application should gain traction in the 2013 to 2015 timeframe. All else being equal, this will drive the overall market growth rate to near 20% in the 2015 to 2020 period. Therefore, across the 2010 to 2020 period, we expect trend line lithium market growth to approximately 12%. Despite the recent weather-related challenges, the 30% capacity expansion at our operations in Argentina continues to progress and we expect to bring the capacity onstream by the end of this year. Accounting for the resident's time necessary to concentrate the additional brine via solar evaporation, we will begin to supply the market with additional product mid-next year. In addition to serving the demand growth of existing customers, we expect the project to significantly lower our overall cost to improve process technology. Given the favorable long-term outlook, we're already reviewing plans for further expansion, which will likely bring on the stages beginning in 2014. We will see some additional near-term capital requirements as a consequence of these plans. This capital will build toward enhancing the natural gas supply to our facility, as well as preparing the evaporation ponds for greater productivity. Let me now turn to BioPolymer. BioPolymer currently accounts for over 70% of Specialty Chemicals revenues or approximately $650 million. BioPolymers comprised of 2 roughly equally sized market-oriented businesses focused on food ingredients and pharmaceutical excipients, respectively. Leading market divisions across these businesses account for more than 90% of BioPolymer revenues. We support both businesses through a common infrastructure that delivers cost-efficient products, core technology and administrative support. Although the food and pharmaceutical markets have different market and competitor drivers, we are able to drive the premium for our products in both businesses by focusing on segments where our products add clear value to our customers ability to sustain and grow their own products. BioPolymer's core markets are growing approximately 4% to 5% per year. Over the last 5 years, BioPolymer has grown its top line at an annual rate of 10% through a combination of organic growth and bolt-on acquisitions. Over the same period, our growth on an earnings basis has been in the low to midteens resulting an overall margin improvement. We believe that today we are among the most profitable suppliers of food ingredients or pharmaceutical excipients. Our success is driven by delivering superior value to our customers. The core expertise is driving improvement in our customers product life cycle through the combination of new technology, improved cost and use and global reach. Partnering with category leaders has been and will remain critical to our success. In food ingredients, we supply the majority of the global food processors and have strong positions with many regional leaders throughout the world. Our products and technology impart critical functionality, including suspension stability in beverages and desired texture to a wide array of food products. In Pharmaceuticals, we have a similar presence with almost key innovators in addition to strong positions with leading generic players. In our experience, it has been the leading customers who have grown the fastest and have the best ability to commercialize new products around the world, whether internally developed or acquired. As these customer expand globally, we've tended to grow with them. Our products and technology provide performance attributes to pharmaceutical tablets across a broad array of active ingredients and manufacturing processes. Core strengths of BioPolymer include a thorough understanding of both the customer application and product technology, deep capabilities in core materials science and process technology and the demonstrated ability continually drive productivity and efficiency improvement. Our success in this latter area have led us to have the lowest delivery cost to customers in almost all of our product lines. Our approach is two-pronged. First, in our operations, we have a strong culture that annually targets to drive out cost to define plans focused on raw material yield improvement, energy savings and low capital capacity debottlenecking. The second advantage stems from how we go to market. Our sales, marketing, innovation and administrative structure is lean and efficient and is significantly lower in cost than most of our competitors. We believe that we can continue to drive productivity to successfully offset cost increases and thus, deliver superior value to our customers. Going forward, our ability to grow our business at above-market rates while expanding margins is based on successfully executing against 4 strategic imperatives. Specifically, we must invest in core products to further strengthen our leadership positions, expand our position in rapidly developing economies, leverage our customer relationships and application expertise by broadening our specialty food ingredient portfolio and expand our pharmaceutical tablets excipient product and technology offering. Let me comment briefly on each of these imperatives. With regard to strengthening our leadership position in core products, we are investing to expand capacity to support growth. We have recently completed an expansion of our Cork, Ireland MCC plant are currently expanding our MCC capacity in Newark, Delaware and our alginate capacity in Norway. We're also evaluating a project to build greenfield MCC capacity in Asia. Our innovation investments include significant focus to introduce new higher functionality attributes to our key products as well as process technology advancements to improve cost and quality. Next, we will continue to focus on growth in rapidly developing economies. Today, these markets account for approximately 1/3 of BioPolymer revenues and continue to offer significant growth opportunities. For example, in Asia, revenues generated this year will be more than double those generated just a few years ago. China and India currently represent BioPolymer's largest markets after the United States and the U.K. Our new Asia innovation center in Shanghai will accelerate our ability to tailor products to local markets and develop new technology we will leverage on a global basis. We will also open a new application laboratory in Singapore in the third quarter to support further growth in Southeast Asia. Of our 7 BioPolymer technology centers, 5 are located in rapidly developing economies. Outside of Asia, Latin America and Eastern Europe, where we have relatively low penetration, are also key regions of focus. On average, these markets will continue to offer attractive growth that is more than double the growth rates we're seeing in developed regions. To expand our portfolio in food ingredients, the next imperative, we are pursuing several organic and external strategies that would broaden our position into other value-added food ingredients. Our deep applications knowledge in texturants provides the foundation for us to leverage our capabilities into adjacent texture ingredients. We're also selectively evaluating specialty ingredient opportunities that can move us outside of texture, broadening our capability to serve our customers in key markets, such as dairy and beverage. Finally, in pharmaceuticals, we have a great franchise with strong customer relationships and expertise in tablet excipients that provide a solid basis to broaden our portfolio. We're focused on adding products which expand capabilities and control the release technologies and in partnering with our customers to improve the potential of drugs with poor solubility. Overall, BioPolymer is an excellent platform that is well positioned for top and bottom line growth. In summary for Specialty Chemicals, I feel good about where we are and where we're headed. We have a track record of strong performance, attractive organic growth opportunities in both BioPolymer and Lithium and a portfolio of attractive external opportunities to augment that growth. Given that, I'm confident we will achieve our Vision 2015 objectives. I'll now turn the call over to Kim Foster, and we'll be happy to answer any questions during the Q&A. Kim?